Single dose pharmacokinetics of piroxicam in cats

doi:10.1046/j.1365-2885.2003.00479.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Journal of Veterinary Pharmacology and Therapeutics

Volume 26 Issue 4, Pages 259 - 263

Published Online: 23 Jul 2003

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 75K) | Related Articles | Citation Tracking

ANTIINFLAMMATORY DRUGS

Single dose pharmacokinetics of piroxicam in cats

H. L. Heeb* R. Chun* D. E. Koch ^† , M. A. Goatley ^† & R. P. Hunter ^†

*Department of Clinical Sciences and;
^†Department of Anatomy and Physiology, Kansas State University, College of Veterinary Medicine, Mosier Hall, Manhattan, KS, USA

Correspondence to Heather L. Heeb, Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Mosier Hall, 1800 Denison, Manhattan, KS 66506, USA. E-mail: hheeb@vet.ksu.edu

Heeb, H. L., Chun, R., Koch, D.E., Goatley M.A., Hunter, R.P. Single dose pharmacokinetics of piroxicam in cats. J. vet. Pharmacol. Therap.26, 259–263.

ABSTRACT

Piroxicam (PIRO) is a nonsteroidal anti-inflammatory drug (NSAID) recognized for its value as a chemopreventative and anti-tumor agent. Eight cats were included in this study. PIRO was administered in a single oral (p.o.) and intravenous (i.v.) dose of 0.3 mg/kg. The study was designed as a randomized complete crossover with a 2-week washout period. Serial blood samples were collected after each dose and plasma was analyzed for PIRO. Pharmacokinetic parameters of PIRO were determined using noncompartmental analysis. PIRO is well absorbed in the cat with a median bioavailability (F) of 80% (range 64–124%). The median i.v. t_1/2 was 12 h (range 8.6–14 h). The median C_max was 519 ng/mL with a corresponding T_max of 3 h. PIRO appears to be rapidly absorbed following p.o. administration in cats with a higher C_max and AUC than in dogs.